Pharming Group (NASDAQ:PHAR) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Pharming Group (NASDAQ:PHAR) announced its quarterly earnings data on Thursday. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.08), FiscalAI reports. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The firm had revenue of $106.50 million during the quarter, compared to the consensus estimate of $111.76 million.

Here are the key takeaways from Pharming Group’s conference call:

• Pharming delivered a strong 2025: total revenues of €376.1M (+27% YoY), Q4 revenue +15%, adjusted operating profit of €36.4M (vs a loss in 2024), operating cash flow of €54.7M, and year-end cash of €181.1M.
• The company reaffirmed 2026 guidance of €405M–€425M revenue (8–13% growth) and operating expenses of €330M–€335M, with >€60M incremental R&D investment while emphasizing continued financial discipline.
• Near‑term pipeline catalysts could be material: enrollment for leniolisib Phase 2 trials is complete with top‑line data expected in H2 2026, and napazimone pivotal enrollment should finish in 2026 with a readout by end‑2027.
• Regulatory uncertainty for Joenja after an FDA complete response letter for the pediatric 4–11 label; a Type A meeting is scheduled end‑March to define resubmission needs, though CHMP and PMDA decisions in EU/Japan are imminent.
• RUCONEST remains resilient in high‑attack HAE patients but faces competitive pressure from new therapies, and management expects a Q1 2026 US RUCONEST revenue headwind of ~7–9% due to inventory normalization.

Pharming Group Stock Up 1.3%

Shares of NASDAQ PHAR opened at $15.34 on Friday. The firm’s 50-day simple moving average is $17.26 and its 200 day simple moving average is $16.05. Pharming Group has a 12-month low of $7.50 and a 12-month high of $21.34. The company has a quick ratio of 2.39, a current ratio of 3.16 and a debt-to-equity ratio of 0.35. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -1,532.47 and a beta of 0.04.

Wall Street Analysts Forecast Growth

PHAR has been the topic of a number of recent research reports. Zacks Research downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. HC Wainwright set a $37.00 target price on Pharming Group and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Finally, Wall Street Zen raised shares of Pharming Group to a “strong-buy” rating in a research note on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Pharming Group has an average rating of “Moderate Buy” and an average price target of $38.00.

Key Pharming Group News

Here are the key news stories impacting Pharming Group this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $37 price target, which supports upside expectations despite model revisions. HC Wainwright note / MarketBeat
• Positive Sentiment: Company reports full‑year 2025 profitability and positive cash flow, a constructive sign for financial stability as it invests in its pipeline. Annual results press summary
• Neutral Sentiment: Management reaffirmed 2026 guidance alongside the Q4 release, which reduces uncertainty but leaves investors focused on execution. Guidance reaffirmation article
• Neutral Sentiment: Earnings call transcript and slide deck are available for detail on drivers (useful for assessing outlook/pipeline spend). Earnings call transcript
• Neutral Sentiment: Coverage notes focus on increased pipeline investment ahead of the new year, a business‑development story that could lift long‑term value but weighs on near‑term margins. Pipeline investment preview
• Negative Sentiment: Q4 results missed expectations: $0.07 EPS vs. $0.15 expected and revenue $106.5M vs. $111.8M expected — the misses are the primary near‑term negative catalyst. Earnings report / transcript
• Negative Sentiment: HC Wainwright trimmed its FY2026 EPS estimate to $0.35 (from $0.49), signaling lowered near‑term earnings expectations even while keeping a bullish view on shares. Analyst estimate change

Hedge Funds Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently made changes to their positions in PHAR. EverSource Wealth Advisors LLC acquired a new stake in shares of Pharming Group during the second quarter worth $32,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group during the fourth quarter worth approximately $224,000. Millennium Management LLC bought a new position in Pharming Group in the 4th quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC grew its holdings in shares of Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares during the period. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.